

UCLA

UCLA Previously Published Works

Title

Baseline characteristics of the North American prodromal Synucleinopathy cohort.

Permalink

<https://escholarship.org/uc/item/7kk8z7dz>

Journal

Annals of Clinical and Translational Neurology, 10(4)

Authors

Elliott, Jonathan
Lim, Miranda
Keil, Allison
[et al.](#)

Publication Date

2023-04-01


















DOI

10.1002/acn3.51738

Peer reviewed

RESEARCH ARTICLE

Baseline characteristics of the North American prodromal Synucleinopathy cohort

Jonathan E. Elliott^{1,2,†} , Miranda M. Lim^{2,3,4,5,6,7,8,†} , Allison T. Keil¹ , Ronald B. Postuma^{9,10} , Amelie Pelletier¹¹, Jean-François Gagnon^{10,11} , Erik K. St. Louis¹² , Leah K. Forsberg¹², Julie A. Fields¹² , Daniel E. Huddleston¹³ , Donald L. Bliwise¹³ , Alon Y. Avidan¹⁴, Michael J. Howell^{15,16} , Carlos H. Schenck¹⁵, Jennifer McLeland¹⁷, Susan R. Criswell¹⁷ , Aleksandar Videnovic^{18,19}, Emmanuel H. During^{20,21} , Mitchell G. Miglis^{20,21} , David R. Shprecher²² , Joyce K. Lee-Iannotti²² , Bradley F. Boeve^{12,#} , Yo-El S. Ju^{17,#}  & the North American Prodromal Synucleinopathy (NAPS) Consortium

¹VA Portland Health Care System, Research Service, Portland, Oregon, USA

²Oregon Health & Science University, Neurology, Portland, Oregon, USA

³Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon, USA

⁴Department of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA

⁵Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon, USA

⁶Neurology, VA Portland Health Care System, Portland, Oregon, USA

⁷Mental Illness Research Education and Clinical Center, VA Portland Health Care System, Portland, Oregon, USA

⁸National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, Oregon, USA

⁹Montreal Neurological Institute, McGill University, Montreal, Québec, Canada

¹⁰Psychology, Université du Québec à Montréal, Montreal, Québec, Canada

¹¹Hôpital du Sacré-Coeur de Montréal, Center for Advanced Research in Sleep Medicine, Montreal, Québec, Canada

¹²Mayo Clinic, Neurology and Medicine, Rochester, Minnesota, USA

¹³Neurology, Emory University, Atlanta, Georgia, USA

¹⁴Neurology, Sleep Disorders Center, University of California Los Angeles, Los Angeles, California, USA

¹⁵Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA

¹⁶Hennepin County Medical Center, Minnesota Regional Sleep Disorders Center, Minneapolis, Minnesota, USA

¹⁷Washington University School of Medicine, St. Louis, Missouri, USA

¹⁸Movement Disorders Unit, Division of Sleep Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

¹⁹Harvard Medical School, Neurological Clinical Research Institute, Boston, Massachusetts, USA

²⁰Psychiatry and Behavioral Sciences, Stanford University, Redwood City, California, USA

²¹Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA

²²Neurology, Banner Sun Health Research Institute, Phoenix, Arizona, USA

Correspondence

Yo-El Ju, Barbara Burton and Reuben Morriss
III Professor of Neurology, Washington
University School of Medicine, 660 S Euclid
Avenue, Box 8111, St. Louis, MO 63110,
USA. Tel: 314-747-3824; Fax: 314-747-3813;
E-mail: juj@wustl.edu

Received: 31 October 2022; Revised: 10
January 2023; Accepted: 14 January 2023

*Annals of Clinical and Translational
Neurology* 2023; 10(4): 520–535

doi: 10.1002/acn3.51738

†Authors contributed equally to the
preparation of this manuscript.

#NAPS Consortium Co-principal Investigators.

Abstract

Objective: Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic-based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenotypic conversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment. **Methods:** Participants ≥ 18 years of age with overnight polysomnogram-confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function. **Results:** Outcomes are primarily reported based on sex (361 total: $n = 295$ male, $n = 66$ female), and secondarily based on history of antidepressant use ($n = 200$ with, $n = 154$ without; with correction for sex differences)

and based on extent of synucleinopathy burden ($n = 56$ defined as isolated RBD, $n = 305$ defined as RBD+ [i.e., exhibiting ≥ 1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ-9; 39.3% and 31%, respectively). **Interpretation:** These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.

Introduction

The North American Prodromal Synucleinopathy (NAPS) Consortium for Rapid Eye Movement (REM) sleep behavior disorder (RBD) was established to facilitate neuroprotective clinical trials for neurodegenerative diseases characterized by synuclein pathology. Such “synucleinopathies,” including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), affect ~2-million people in the US, have a staggering economic footprint,¹ and lack treatments to prevent inevitable severe disability and death. To date, all neuroprotective therapies (defined by disease-modifying treatments) for synucleinopathy patients have failed,^{2,3} with one possible explanation being that the pathological changes present at time of clinical diagnosis were already too advanced and no longer modifiable, or otherwise did not modify the underlying clinical syndrome. Treatments may have greater chance of efficacy during the prodromal stage (i.e., synuclein pathology prior to overt symptoms). Currently, there are no established/widely used biomarkers for detecting prodromal synucleinopathies.

RBD is a disorder characterized by a lack of muscle atonia during REM sleep and dream enactment behaviors,^{4,5} and is strongly associated with synucleinopathies.^{6–9} In addition to a high proportion of individuals with overt synucleinopathies having RBD, even among individuals with “idiopathic” RBD, 40%–70% phenoconvert/develop an overt synucleinopathy within 5–10 years.^{10–12} (henceforth “RBD” will be used for RBD occurring in the absence of neurological diseases. Additionally, since the term “isolated RBD” has been used interchangeably with “idiopathic RBD” in the literature, we note that the NAPS Consortium defines “isolated RBD” differently, i.e., without accompanying signs/symptoms of neurodegeneration, as detailed in the Methods section). Single-center studies have demonstrated that many individuals with RBD exhibit incipient abnormalities in motor function, cognition, autonomic function, color vision, olfaction, and brain imaging, similar to but milder than in overt synucleinopathies.^{13,14} Abnormal synuclein aggregates in the

enteric nervous system, submandibular glands, and skin have been reported in RBD.^{15–18} Taken together, RBD should be considered a prodromal stage of an evolving synucleinopathy in most individuals ≥ 50 years old, which could suggest RBD may offer an opportunity to test potential treatments at early stages of synucleinopathy, when disease progression may be more susceptible to modification.

Building upon existing RBD research groups (e.g., the International RBD Study Group),¹⁹ the NAPS Consortium (<https://www.naps-rbd.org>) comprises a coordinated effort across nine sites in North America to establish an RBD cohort prospectively assessed by standardized assessments and biomarker collection. Herein we describe the baseline characteristics of the NAPS Consortium, a primarily but not exclusively clinic-based cohort, which at present, reflecting a single cross-sectional timepoint (prospective, longitudinal follow-up on this cohort are ongoing). Data are presented describing the whole cohort, with special attention placed on sex, whether prodromal synucleinopathy features are present, antidepressant use, and family history, given that each of these traits have proved meaningful in past studies.

Materials and methods

Overview

A complete methodological description of the NAPS Consortium protocol is published in a separate overview paper (Ju et al. Pending). Briefly, participants >18 years of age with polysomnogram-confirmed RBD by ICSD-3 criteria²⁰ who did not have a diagnosis of PD,²¹ dementia of any type,²² MSA,²³ or narcolepsy²⁴ were enrolled from nine sites across North America. From August 2018 to April 2021, total $n = 361$ participants were enrolled at Washington University School of Medicine ($n = 26$), Mayo Clinic Rochester ($n = 50$), University of Minnesota ($n = 30$), Center of Advanced Research in Sleep Medicine at the *Hôpital du Sacré-Coeur de Montréal* ($n = 94$), Harvard/Massachusetts General Hospital ($n = 26$), Emory

University ($n = 32$), University of California Los Angeles ($n = 32$), Stanford University ($n = 20$), and the VA Portland Health Care System ($n = 51$). Participants from a tenth site, at Banner Sun Health, are not included in this analysis. Referrals were made primarily from clinics offered on a consecutive basis and supplemented by community referrals through the www.naps-rbd.org website. There were no *a priori* demographic for goals recruitment, and information regarding those who chose not to participate was not retained. This study was performed according to the *Declaration of Helsinki* and approved by the Institutional Review Boards at each enrollment site. All participants provided written informed consent prior to participation.

Data collection procedures and practices were rigorously standardized across sites, which included structured interviews and questionnaires on health history, structured neurological, and physical examinations, and an objective test battery of cognitive, motor, autonomic, and sensory functions. If available, a co-participant (a spouse, family member, or friend who knows the participant well) provided information via structured interviews and written questionnaires. Variables presented in this analysis are detailed below; according to the NAPS1 REDCap database export dated May 26, 2022 prior to complete import into the NAPS2 RAVE database. Biofluid assay data, polysomnograms, data from participants enrolling after April 2021, and data from longitudinal study visits are not presented in this analysis.

Based on the clinical evaluation, questionnaires, exam, and objective tests, the clinician at each site (a board-certified neurologist) completed a standardized, structured assessment to render clinical diagnoses. Determinations were supported by a quarterly, panel-based adjudication process with three or more NAPS clinicians. Participants were categorized as “RBD+” indicating one or more abnormalities (symptoms, signs, or test results attributable to a neurodegenerative cause) in any of the cognitive, motor, autonomic, or sensory domains ($n = 305$); or as “isolated RBD” indicating no abnormalities were detected during the clinical evaluation and test battery ($n = 56$). Participants with diagnosis of any overt neurodegenerative disease ($n = 6$; rare, since a previously known diagnosis would have been exclusionary) are excluded from this analysis.

RBD and sleep measures

A NAPS-specific structured interview queried for RBD symptoms, frequency, severity, treatments, and possible temporal relationship with any antidepressant or other medications. Diagnoses of sleep apnea (obstructive or central), restless legs syndrome, and periodic limb

movement were determined during the clinician’s structured interview. The severity and frequency of RBD symptoms was assessed by the RBD Severity Scale (RBDSS),²⁵ completed by the participant as well as bed-partner (RBDSS-BP), if available. Other sleep-related measures included the Epworth Sleepiness Scale (ESS) to measure daytime sleepiness²⁶ and the Scales for Outcomes in PD-Sleep (SCOPA-Sleep) which queries nighttime sleep quality and daytime sleepiness.²⁷

Other health history and questionnaires

Demographic information and health history (including comprehensive family history) were obtained via structured interview and forms, including those from the Uniform Data Set version 3 (UDS3), from the National Alzheimer Coordinating Center (<https://nacccdata.org/data-collection/forms-documentation/uds-3>) and custom NAPS-specific forms. Questionnaires assessing neuropsychiatric function included the Beck Anxiety Inventory (BAI), Patient Health Questionnaire-9 (PHQ-9) for depression, the Post-Traumatic Stress Disorder (PTSD) checklist (PCL-5),²⁸ and an informant-completed Neuropsychiatric Inventory-Questionnaire (NPI-Q).²⁹ Autonomic function was assessed using the Scales for Outcomes in PD-Autonomic Dysfunction (SCOPA-AUT).³⁰

Neurological test battery

Participants underwent a broad neurological test battery including objective tests of cognitive, motor, autonomic, and sensory (color vision and smell) function. Cognitive assessments included the psychometric battery from the UDS3 standard and LBD modules³¹: Montreal Cognitive Assessment (MoCA),³² the Craft Story 21 (immediate and delayed), the Benson Complex Figure Copy (immediate and delayed), Number Span Test Forward and Backward, Trail Making Test parts A and B, categorical and phonemic fluency (animals, vegetables, words beginning with F and L), Multilingual Naming Test (MINT), the Speeded Attention Task,³³ and the Noise Pareidolia Task.^{34,35} Raw scores were adjusted for age, sex, and years of education, and Z-scored. Scores ≥ 1.5 standard deviations below the mean were considered abnormal, and two abnormal tests in a domain (memory, attention/executive, visuospatial, or language) were required for the domain to be considered abnormal.

Motor function was assessed via the Timed Up and Go (TUG),³⁶ Purdue Pegboard,³⁷ and Alternate Tap tests. Collectively, these assessments evaluated participants’ gross motor function, ability to sit/stand/walk, fine motor control and coordination of the limbs and digits, and

overall reaction/movement speed. Additionally, the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) was administered, and part 3 of this assessment includes a clinician-quantified rating of gross and fine motor function.³⁸

Autonomic function was measured with orthostatic blood pressure, in which blood pressure was measured after lying supine for 5 min, then 3 min after standing. Impaired orthostatic tolerance was defined as ≥ 20 mm Hg decrease in systolic blood pressure and/or a ≥ 10 mm Hg decrease in diastolic blood pressure. Severe orthostatic intolerance was defined as ≥ 30 mm Hg decrease in systolic blood pressure and/or a ≥ 15 mm Hg decrease in diastolic blood pressure.^{39,40} Additionally, subjective autonomic function was assessed using the Scales for Outcomes in PD—Autonomic Dysfunction (SCOPA-AUT).³⁰

The Brief Smell Identification Test (B-SIT; Version A, Sensonics Inc. NJ, USA)⁴¹ assessed overall olfaction and scent discrimination, with higher scores indicating greater olfactory function. Sex- and age-adjusted cutoffs were used to define abnormal results, however, in general scores ≤ 8 indicate impaired olfaction.⁴² The Farnsworth Munsell 100 Color Hue test (FM-100)⁴³ assessed participants color discrimination ability, with higher scores indicating worse color vision. Age-adjusted cutoff were used for FM-100 scores, however, in general scores >100 suggest poor color discrimination.⁴⁴ Participants self-reported any color blindness or subjective smell impairment.

Statistical analyses

Statistical analyses were performed with SPSS and Graph-Pad Prism v9, with alpha at 0.05. Data are presented as mean, standard deviation, number, and percentage of the whole. Data for the whole group (Tables 1–4) are presented as descriptive statistics. Special emphasis was placed on the description of these data considering sex (Tables 1, 2, and 5, 6) and is similarly presented with comparisons between groups analyzed with either unpaired two-tailed Student's *t* test, Mann–Whitney *U* test, or χ^2 test, as appropriate. Group differences between sex within RBD and sleep-related outcomes (Table 2) were corrected for antidepressant usage defined as past or current self-reported antidepressant use using a generalized linear model univariate analysis. These data are also shown based on two sub-analyses, (1) with participants separated based on their self-reported history of antidepressant usage (i.e., participants with any past or current use vs. participants who have never used antidepressants; Table 3), and (2) with participants separated based on their clinician determined degree of synucleinopathy burden and evidence of neurodegeneration (i.e., isolated

RBD vs. RBD+; Table 4), with comparisons between groups analyzed with either unpaired two-tailed Student's *t* test, Mann–Whitney *U* test, or χ^2 test, as appropriate. Throughout the presentation of results, *p*-values should be interpreted with the understanding that corrections for multiple testing were not done and that potential issues surrounding selection and confounding were not robustly modeled.

Table 1. Demographic characteristics.

	Whole Cohort <i>n</i> = 361	Male <i>n</i> = 295	Female <i>n</i> = 66
Age, years	64.9 \pm 10.1	65.2 \pm 10.1	63.5 \pm 9.7
Age, range (median; IQR)	28–85 (67; 11)	28–85 (68; 12)	30–81 (64; 13)
Handedness, right	305 (85%)	248 (84%)	58 (88%)
Ethnicity and race			
Ethnicity, <i>Hispanic/Latinx</i>	12 (3%)	9 (3%)	3 (5%)
Race, <i>White</i>	326 (90%)	266 (90%)	60 (91%)
Race, <i>Black or African American</i>	8 (2%)	7 (2%)	1 (1%)
Race, <i>other</i>	27 (8%)	22 (8%)	5 (8%)
Education			
Education, ≤ 12 years	56 (16%)	48 (16%)	9 (14%)
Education, 13–14 years	51 (14%)	41 (14%)	11 (16%)
Education, 15–18 years	185 (52%)	147 (50%)	38 (58%)
Education, ≥ 19 years	65 (18%)	59 (20%)	8 (12%)
Marital status			
Marital status, <i>married/domestic partner</i>	306 (85%)	236 (88%)	42 (70%)*
Marital status, <i>divorced/separated</i>	33 (9%)	21 (7%)	12 (18%)*
Marital status, <i>widowed</i>	9 (2%)	5 (2%)	4 (6%)*
Marital status, <i>never married/annulled</i>	13 (4%)	9 (3%)	4 (6%)
Living situation			
Living with spouse/partner	311 (86%)	265 (90%)	48 (73%)
Living alone	39 (11%)	24 (8%)	14 (21%)
Living with friend/roommate	11 (3%)	6 (2%)	4 (6%)
Living independently	344 (95%)	283 (96%)	62 (94%)
Living with some assistance	17 (5%)	12 (4%)	4 (6%)
Living in single/multi-family residence	356 (99%)	289 (98%)	66 (100%)
Living in community/group living	4 (1%)	6 (2%)	0 (0%)

Data are presented as mean \pm standard deviation, or raw frequency count with percent of the total number of available responses in parentheses.

**p* < 0.05 female versus male.

Table 2. RBD and other sleep characteristics.

	Whole Cohort <i>n</i> = 361	Male <i>n</i> = 295	Female <i>n</i> = 66
RBD history			
Earliest age of onset, years	51.1 ± 16.3	51.6 ± 18.1	48.9 ± 21.0
Movement/talking	352 (98%)	288 (98%)	64 (97%)
Movement/talking w/ dreams, always	203 (56%)	164 (56%)	39 (59%)
RBD behavior without medication, daily	124 (34%)	110 (37%)	14 (21%)*
RBD behavior with medication, daily	80 (22%)	73 (25%)	7 (11%)*
RBD behavior: injured self, ever	202 (56%)	173 (59%)	29 (44%)
RBD behavior: injured self, past 6 mo	85 (24%)	76 (26%)	9 (14%)
RBD behavior: injured bed partner, ever	143 (40%)	132 (45%)	11 (17%)*
RBD behavior: injured bed partner, past 6 mo	58 (16%)	53 (18%)	5 (8%)
Other sleep disorders			
Obstructive sleep apnea	198 (55%)	173 (59%)	25 (38%)*
Central sleep apnea	29 (8%)	27 (9%)	2 (3%)
Restless legs syndrome	65 (18%)	53 (18%)	12 (18%)
Insomnia	101 (28%)	74 (25%)	25 (38%)
Periodic limb movement disorder	56 (16%)	45 (15%)	11 (17%)
Daytime somnolence	26 (7%)	22 (8%)	4 (6%)
Medication use			
Melatonin, past or present use	175 (49%)	148 (50%)	27 (41%)
Clonazepam, past or present use	133 (37%)	110 (38%)	22 (33%)
Antidepressant, past or present use	200 (55%)	151 (51%)	49 (74%)*
Antidepressant/RBD association	23 (6%)	17 (6%)	6 (9%)
Other, past or present use	51 (14%)	40 (14%)	11 (17%)
Sleep questionnaires			
SCOPA sleep (participant), score	11.8 ± 6.8	11.9 ± 6.41	11.3 ± 6.2
Day, sub-score	3.4 ± 3.0	3.5 ± 3.03	3.0 ± 3.0
Night, sub-score	8.4 ± 4.7	8.4 ± 4.67	8.3 ± 4.9
SCOPA sleep (co-participant), score	12.5 ± 7.2	13.0 ± 7.3	10.4 ± 6.3*
Day, sub-score	4.0 ± 3.6	4.2 ± 3.7	2.6 ± 2.6*
Night, sub-score	8.6 ± 5.3	8.8 ± 5.4	7.7 ± 4.6
Epworth Sleepiness Scale, score	6.5 ± 4.7	6.5 ± 4.7	6.4 ± 4.9

Data are presented as mean ± standard deviation, or raw frequency count with percent of the total number of available responses in parentheses. Other psychotropic/neurologic/sleep-related medications use include zolpidem, trazodone, cannabidiol, lorazepam, prazosin, ropinirole, donepezil, pimavanserin, diphenhydramine, and gabapentin. RBDSS, RBD Severity Scale; SCOPA, Scales for Outcomes in Parkinson's Disease.

**p* < 0.05 female versus male.

Table 3. RBD characteristics and sleep outcomes based on antidepressant use.

	Any use <i>n</i> = 200	No use <i>n</i> = 154
Age, years	63.4 ± 10.5	67.0 ± 9.1
Sex, male	149 (75%)	140 (91%)*
Hypertension	80 (40%)	57 (37%)
Hypercholesterolemia	73 (37%)	19 (12%)
RBD behavior and characteristics		
Earliest age of onset, years	47.7 ± 17.6	55.8 ± 17.4*
Movement/talking	197 (99%)	149 (97%)
Movement/talking w/ dreams, always	114 (57%)	89 (58%)
RBD behavior w/o medication, daily	72 (36%)	50 (33%)
RBD behavior w/ medication, daily	45 (22%)	32 (21%)
RBD behavior: injured self, ever	113 (57%)	86 (56%)
RBD behavior: injured self, 6 mo	54 (27%)	29 (19%)*
RBD behavior: injured bed partner, ever	84 (42%)	58 (38%)
RBD behavior: injured bed partner, 6 mo	34 (17%)	23 (15%)
Medication use		
Melatonin, past or present use	77 (39%)	53 (34%)
Clonazepam, past or present use	91 (46%)	82 (53%)
Other, past or present use	46 (23%)	3 (2%)*
Other sleep disorders		
Obstructive sleep apnea	116 (58%)	74 (48%)
Restless legs syndrome	50 (25%)	14 (9%)*
Insomnia	67 (34%)	31 (20%)*
Periodic limb movement disorder	37 (19%)	18 (12%)
Sleep questionnaires		
SCOPA Sleep (participant), score	13.2 ± 6.7	9.9 ± 5.5*
SCOPA Sleep (co-participant), score	13.8 ± 7.6	10.7 ± 6.3*
Epworth Sleepiness Scale, score	7.11 ± 5.0	5.6 ± 4.1*

Data are presented as mean ± standard deviation, or raw frequency count with percent of the total number of available responses in parentheses. Data missing on *n* = 6 participants. Other psychotropic/neurologic/sleep-related medications use include zolpidem, trazodone, cannabidiol, lorazepam, prazosin, ropinirole, donepezil, pimavanserin, diphenhydramine, and gabapentin.

SCOPA, Scales for Outcomes in Parkinson's Disease.

**p* < 0.05 versus any use.

Results

Demographics

The participant cohort (*n* = 361; Table 1) was predominately male (81.7%), middle/old-aged (64.9 ± 10.1 years), white (90.3%), right-handed (84.8%), married (77.0%), with >15 years of education (69.2%). Among statistically significant demographic differences between men and women, a greater proportion of men were married/living as a domestic partnership (80% vs. 63.6%, *p* = 0.004), while a greater proportion of women were divorced/separated (16.7% vs. 4.7%, *p* < 0.001) or were widowed (6.1% vs. 1.7%, *p* = 0.04).

Table 4. RBD characteristics and sleep outcomes in isolated RBD.

	Isolated RBD <i>n</i> = 56	RBD+ <i>n</i> = 305
Age, years	57.3 ± 13.4	66.3 ± 8.6*
Sex, male	37 (66%)	258 (85%)*
Hypertension	15 (27%)	125 (41%)*
Hypercholesterolemia	17 (30%)	116 (38%)
RBD behavior and characteristics		
Earliest age of onset, years	42.9 ± 20.9	52.5 ± 17.5*
Movement/talking	55 (98%)	297 (97%)
Movement/talking w/ dreams, always	33 (59%)	170 (56%)
RBD behavior w/o medication, daily	9 (16%)	115 (38%)*
RBD behavior w/ medication, daily	3 (5%)	77 (25%)*
RBD behavior: injured self, ever	23 (41%)	179 (59%)*
RBD behavior: injured self, 6 mo	8 (14%)	77 (25%)
RBD behavior: injured bed partner, ever	18 (32%)	125 (41%)
RBD behavior: injured bed partner, 6 mo	8 (14%)	50 (16%)
Medication use		
Melatonin, past or present use	19 (34%)	114 (37%)
Clonazepam, past or present use	25 (45%)	150 (49%)
Antidepressant, past or present use	23 (41%)	125 (41%)
Antidepressant/RBD association	7 (13%)	16 (5%)
Other, past or present use	13 (23%)	38 (12%)
Other sleep disorders		
Obstructive sleep apnea	35 (62%)	163 (53%)
Restless legs syndrome	6 (11%)	59 (19%)
Insomnia	19 (34%)	80 (26%)
Periodic limb movement disorder	7 (13%)	49 (16%)
Sleep questionnaires		
SCOPA Sleep (participant), score	12.2 ± 6.2	11.7 ± 6.4
SCOPA Sleep (co-participant), score	11.0 ± 6.8	12.7 ± 7.2
Epworth Sleepiness Scale, score	6.9 ± 5.3	6.4 ± 4.6

Data are presented as mean ± standard deviation, or raw frequency count with percent of the total number of available responses in parentheses. See text for definition of isolated RBD. Other psychotropic/neurologic/sleep-related medications use include zolpidem, trazodone, cannabidiol, lorazepam, prazosin, ropinirole, donepezil, pimavanserin, diphenhydramine, and gabapentin. SCOPA, Scales for Outcomes in Parkinson's Disease.

**p* < 0.05 versus isolated RBD.

RBD characteristics and sleep

The overall cohort reported mean RBD symptom onset at age 51.1 ± 16.3 (Table 2). There were nine participants reporting an age of onset ≤16 years, possibly reflecting Parasomnia Overlap Disorder that progressed to RBD over time⁴⁵; for the purpose of determining the group average, these were considered as 16 years of age. The pre-adjusted group average was not significantly different at 50.6 ± 15.2 years of age. RBD behavior was commonly associated with prior injury to themselves (56.0%) and their bed partners (39.6%). Medication usage of interest

included melatonin (48.5%) and clonazepam (36.8%). Antidepressant usage history was reported by 55.4%, of whom only 11.5% indicated antidepressant medication worsened RBD symptoms. Other current medications are listed in Table 2. Roughly half (54.8%) of the overall population had a history of obstructive sleep apnea (8.0% with central sleep apnea). There was a high frequency of insomnia (27.4%), restless legs syndrome (18.0%), and periodic limb movement disorder (15.5%). Participant SCOPA Sleep (total) scores averaged 11.8 ± 6.4, with bed partners/co-participants reporting scores of 12.5 ± 7.2 for the participant, suggesting mild impairment on average. The mean Epworth Sleepiness Scale score was 6.5 ± 4.7, which is in the normal range.

With regard to sex differences, RBD symptom onset occurred ~3 years earlier in women than men, a difference that was not statistically significant (48.9 ± 21.0 vs. 51.6 ± 18.1 years of age; *p* = 0.244). Women reported fewer RBD-related injuries, including to their bed partner (16.7% vs. 44.7%, *p* = 0.038). Despite the greater proportion of women reporting a history of antidepressant usage (74.2% vs. 51.2%; *p* < 0.001), women less frequently associated RBD behavior with medication use (24.7% vs. 10.6%; *p* = 0.027). None of these RBD-related differences in women were associated with history of antidepressant usage. With respect to other sleep disorders, women reported higher rates of insomnia (37.9% vs. 25.1%, *p* = 0.038), and lower rates of obstructive sleep apnea (37.9% vs. 58.6%; *p* = 0.01), of which only the latter was statistically significant after adjustment for antidepressant usage. The only difference in self-reported sleep scores was seen in the co-participant's report of the SCOPA-Sleep total score (10.4 ± 6.3 vs. 12.9 ± 7.3, *p* = 0.005) and daytime sub-score (2.6 ± 2.6 vs. 4.2 ± 3.7, *p* = 0.005).

Antidepressant usage within the overall population was examined based on participants reporting any history of antidepressant usage (previous or current; no clinically relevant differences were noted when comparing only previous or only current usage) compared to participants with no history of antidepressant usage (Table 3). Despite similar age of enrollment, RBD symptom onset occurred 8.1 years earlier in participants with a history of antidepressant usage (47.7 ± 17.5 vs. 55.8 ± 17.4 years of age; *p* < 0.001). Restless legs syndrome (25.0% vs. 9.1%; *p* < 0.001), and insomnia (33.5% vs. 20.1%; *p* = 0.004) were more frequent in participants with antidepressant usage. Medications reported to worsen RBD symptoms primarily included antidepressants including selective serotonin reuptake inhibitors (SSRI; fluoxetine, paroxetine, sertraline, escitalopram), selective norepinephrine reuptake inhibitors (SNRI; venlafaxine, duloxetine), norepinephrine dopamine reuptake inhibitors (NDRI;

bupropion), tri/tetracyclic antidepressants (TCA; amitriptyline, nortriptyline, mirtazapine, amitriptyline), and monoamine oxidase inhibitors (MAOI; phenelzine), anxiolytics (buspirone), dopamine agonists (pramipexole), and to a lesser extent, sedative-hypnotics, and antihistamines (zolpidem, diphenhydramine, trazodone).

RBD and sleep-related outcomes were compared between participants determined to have isolated RBD (i.e., those with no other signs of neurodegeneration) and those with possible neurodegenerative signs (i.e., RBD+; Table 4). Isolated RBD participants were younger (57.3 ± 13.5 vs. 66.3 ± 8.6 , $p < 0.001$), reported an earlier age of RBD symptom onset (42.9 ± 20.9 vs. 52.5 ± 17.5 , $p < 0.001$), and were more likely to be female ($p < 0.001$). Isolated RBD participants less frequently associated RBD behavior with medication usage (5.4% vs. 25.2%, $p < 0.001$), and reported lower rates of RBD behavior being associated with self-injury (41.1% vs. 58.7%, $p = 0.011$). Differences may be explained by the higher proportion of women (and greater rate of antidepressant use) in the isolated RBD group, as there was no difference in the duration between symptom onset/diagnosis and NAPS referral with respect to isolated RBD versus RBD+, men versus women.

Health history

The most commonly reported health problems in the cohort (Table 5) were hypercholesterolemia (36.8%), arthritis (32.1%; primarily osteoarthritis), hypertension (38.8%), thyroid disease (14.1%), type II diabetes (11.6%), and atrial fibrillation (10.5%). Women reported ~40% lower rate of hypercholesterolemia (27.3% vs. 39.0%; $p = 0.05$) and hypertension (21.2% vs. 42.7%; $p = 0.001$), and ~50% higher rate of arthritis (50.0% vs. 28.1%; $p < 0.001$) and thyroid disease (24.2% vs. 11.9%; $p = 0.009$) than men.

Autonomic function, as assessed by SCOPA-AUT, averaged 13.5 ± 7.8 in the overall cohort, not significantly different between men and women. Urinary and bowel incontinence, as well as orthostatic hypotension were not different between men and women. Men reported a nearly two-fold higher rate of sexual dysfunction compared to women (68% vs. 37%).

Approximately 27% of the cohort reported a history of traumatic brain injury (TBI) occurring on average 31 years ago, which was more common in men (29.2% vs. 16.7%; albeit non-significant $p = 0.056$). Similarly, TBI-related metrics (i.e., with or without loss of consciousness) were also potentially higher in men than women.

The most common mental health problems were anxiety (39.3%) and depression (recent, <2 years ago, 31.0%;

Table 5. General, cardio/cerebrovascular, neurological, and mental health history.

	Whole Cohort <i>n</i> = 361	Male <i>n</i> = 295	Female <i>n</i> = 66
General health			
Hypercholesterolemia	133 (37%)	115 (39%)	18 (27%)*
Arthritis	116 (32%)	83 (28%)	33 (50%)*
Thyroid disease	51 (14%)	35 (12%)	16 (24%)*
Type II diabetes	42 (12%)	35 (12%)	7 (11%)
Vitamin B12 deficiency	30 (8%)	22 (8%)	8 (12%)
Seizures	10 (3%)	7 (2%)	3 (5%)
Cardiovascular and cerebrovascular			
Hypertension	140 (39%)	126 (43%)	14 (21%)*
Atrial fibrillation	38 (11%)	33 (11%)	5 (8%)
Myocardial infarction	20 (6%)	18 (6%)	2 (3%)
Stroke	10 (3%)	9 (3%)	1 (2%)
Other cardiovascular disease	42 (12%)	33 (11%)	9 (13%)
Autonomic function			
SCOPA-AUT, score	13.5 ± 7.8	13.5 ± 7.5	13.3 ± 9.0
Urinary incontinence	60 (17%)	49 (17%)	11 (17%)
Bowel incontinence	13 (4%)	9 (3%)	4 (6%)
Traumatic brain injury			
Traumatic brain injury, ever	97 (27%)	86 (29%)	11 (17%)
With LOC <5 min	56 (16%)	49 (17%)	7 (11%)
With LOC >5 min	26 (7%)	22 (8%)	4 (6%)
Without LOC	40 (11%)	35 (12%)	5 (5%)
Recency, years	31 ± 18	31 ± 16	28 ± 15
Mental health			
BAI, score	8.1 ± 8.8	7.6 ± 8.4	10.3 ± 10.3
Anxiety, self-report	142 (39%)	103 (35%)	39 (59%)*
PHQ-9, score	5.2 ± 5.4	5.1 ± 5.3	6.0 ± 5.5
Depression, <2 years self-report	112 (31%)	91 (31%)	21 (32%)
PCL-5, score	12.3 ± 15.6	12.2 ± 15.5	12.7 ± 15.6
PTSD, self-report	48 (13%)	40 (14%)	8 (12%)
Obsessive-compulsive disorder	21 (6%)	18 (6%)	3 (5%)
Developmental disorder	33 (9%)	25 (8%)	8 (12%)
Neuropsychiatric inventory			
Delusions	17 (4%)	15 (5%)	2 (3%)
Hallucinations	20 (6%)	18 (6%)	2 (3%)
Anxiety	80 (22%)	66 (22%)	14 (21%)
Apathy/indifference	72 (20%)	68 (23%)	4 (6%)*
Tobacco and alcohol use			
Tobacco, within the past 30 days	27 (7%)	24 (8%)	3 (5%)
Tobacco, total years smoked	63.6 ± 34.6	63.9 ± 35.1	62.2 ± 36.6
Alcohol, within the past 90 days	272 (75%)	224 (76%)	48 (73%)
Alcohol, ≥ 3 drinks per week	68 (19%)	62 (21%)	6 (9%)

Data are presented as mean \pm standard deviation, or raw frequency count with percent of the total number of available responses in parentheses. Other cardiovascular disease includes, arrhythmias/bundle branch block ($n = 8$), congenital heart defects ($n = 4$).

BAI, Beck Anxiety Inventory; BP, blood pressure; LOC, loss of consciousness; PCL-5, post-traumatic stress disorder checklist for DSM-V; PHQ-9, Patient Health Questionnaire-9; SCOPA-AUT, scales for Outcomes in Parkinson's Disease Autonomic Function.

* $p < 0.05$ female versus male.

or inactive, >2 years ago, 29.5%). Individuals self-reporting anxiety and depression averaged 14.4 ± 11.4 and 9.1 ± 6.1 for BAI and PHQ-9 scores, respectively. However, self-reported BAI and PHQ-9 scores in the overall group averaged 8.1 ± 8.8 and 5.2 ± 5.4 , respectively, which are scores below clinical thresholds for anxiety or depression (BAI scores <16 indicate mild to no anxiety; PHQ-9 scores <10 indicate mild to no depression). Considering previously reported associations between PTSD and RBD,⁴⁶ the overall rate of PTSD was 24.1% in this cohort, with no difference between men and women.

The Neuropsychiatric Inventory assessed domains related to delusions, hallucinations, anxiety, and apathy/indifference. This cohort had low rates of current delusions or hallucinations (~4%–5%), whereas anxiety was reported at 22.2% and apathy/indifference at 19.7%. Although men had higher rates in the “apathy/indifference” (22.7% vs. 6.1%; $p < 0.001$) domain, no sex-related differences were found in the other three features.

Neurological test battery results

The cognitive battery revealed relatively normal mean scores in the overall cohort, with women having better scores in the MoCA (27.1 ± 4.5 vs. men 26.0 ± 5.3 ; $p = 0.011$), worse scores on the MINT (29.6 ± 2.6 vs. 30.2 ± 2.6 ; $p = 0.047$), and improved phonemic/categorical verbal fluency (Table 6; Fig. 1). However, this result is inclusive of participants categorized as having isolated RBD, who, by definition, are not cognitively impaired and did not have abnormal psychometric test performance. Indeed, 38.3% of participants ($n = 116$) with RBD+ had MoCA scores ≤ 25 (threshold for defining abnormal scores⁴⁷), and 27.6% of these individuals ($n = 32$) met criteria for mild cognitive impairment.⁴⁸

Mean motor test and examination scores were in the normal range (Table 6; Fig. 1); however, among RBD+ participants, ~8% were abnormal on the TUG (defined as ≥ 13.5 s), ~30% were abnormal on the Purdue pegboard test (defined as <9), ~50% were abnormal on the alternate tap test (defined as <165) and ~25% were abnormal on the MDS-UPDRS part 3 assessment (defined by scores >4).

A relatively large proportion of participants had autonomic impairment as assessed by orthostatic tolerance testing. Orthostatic hypotension was present in 27.7% of the cohort (defined by a systolic and/or diastolic blood pressure drop of >20/10 mm Hg, respectively, after 3 min of standing), with 13.3% having values in the severe range (i.e., systolic and/or diastolic drop >30/15 mm Hg); there were no differences between men and women.

Average FM-100 scores in non-color-blind participants were 143.6 ± 97.6 , indicating 74% of the cohort was

abnormal, with women showing slightly better mean color vision (119 ± 89 vs. 149 ± 101 ; $p = 0.024$) (Table 6; Fig. 1). Consistent with known sex differences, there was a lower frequency of color blindness in women compared to men (3.0% vs. 6.8%; albeit non-significant $p = 0.26$). Olfactory impairment was self-reported in 21.9% of the overall population, however, 57% showed abnormal BSIT scores. Similarly, women had better olfaction than men on the BSIT (8.2 ± 2.7 vs. 7.0 ± 3.1 ; $p = 0.004$). Among RBD+ participants, ~50% were abnormal in both color vision and olfactory function.

Family history

Participants in this study provided extensive family history information (Fig. 2), however, these data rely on their individual knowledge and recall for these specific conditions (responses for “unknown” were not recorded). Familial history for probable RBD was predominant in males, with 2.6% of brothers and 4.7% of fathers reportedly having probable RBD, compared to a rate of 0.8% for sisters and mothers each. The rate of probable RBD in grandparents was consistent across paternal and maternal sides (0.3%). PD and DLB showed a male association (PD 3.2%, DLB 1.8% in fathers vs. PD 2.1% and DLB 1.3% in mothers). No evident maternal or paternal association was seen for MSA or other neurological disorders. The rate of the broad categorization of other sleep disorders was 9.5% in fathers and 4.5% in mothers. Alzheimer’s disease and dementia NOS showed a stronger maternal association (16.9% in mothers and 9% in fathers), which was consistent in the previous generation (9.7% in maternal grandmothers, compared to 1%–3% in maternal grandfathers, paternal grandmothers, and paternal grandfathers).

Discussion

We report characteristics of the initial NAPS Consortium cohort as measured through a standardized, comprehensive clinical assessment. Consistent with previous literature, we found a male preponderance for RBD (~80%),^{49–52} and we confirmed prior findings that suggested antidepressant medications are associated with RBD presenting earlier in life and in women. We identified a high rate of subtle neurological dysfunction in RBD, with 84% of our cohort having an abnormality in at least one neurological domain. We also describe a comprehensive neurological family history in RBD, with RBD and PD family history higher in male relatives, and dementia family history higher in female relatives.

Even across 9 sites, there was a high male:female ratio in our RBD cohort, yet a striking lack of differences

Table 6. Cognition, motor, autonomic, and sensory function.

	Whole cohort <i>n</i> = 361	Abnormal	Male <i>n</i> = 295	Female <i>n</i> = 66
Cognition				
Montreal cognitive assessment	26.2 ± 3.0	116 (38%)	26.0 ± 5.3	27.1 ± 4.5*
Craft story				
Immediate verbatim	13.1 ± 5.2	99 (27%)	13.0 ± 5.1	13.3 ± 6.0
Delay verbatim	15.3 ± 6.6	93 (26%)	15.1 ± 6.7	16.3 ± 6.9
Benson				
Immediate	15.5 ± 1.4	50 (14%)	15.5 ± 2.1	15.6 ± 2.4
Delay	11.2 ± 3.2	56 (15%)	11.2 ± 3.4	10.9 ± 4.1
Number span				
Total forward	8.3 ± 2.4	23 (6%)	8.3 ± 2.4	8.4 ± 2.3
Total backward	6.8 ± 2.3	44 (12%)	6.7 ± 2.3	7.1 ± 1.9
Trails A, <i>seconds</i>	41.5 ± 73.6	99 (27%)	43.1 ± 80.9	34.3 ± 17.0
Trails B, <i>seconds</i>	103.5 ± 119.1	81 (22%)	106.0 ± 128.6	92.3 ± 58.7
Multilingual naming test	30.1 ± 2.1	47 (13%)	30.17 ± 2.6	29.6 ± 2.6*
Phonemic/categorical fluency				
F words	13.8 ± 5.1	46 (13%)	13.5 ± 5.2	15.1 ± 5.1*
L words	12.8 ± 5.2	61 (17%)	12.5 ± 5.2	14.1 ± 5.1*
Animals	20.3 ± 5.5	55 (15%)	20.1 ± 5.5	21.2 ± 5.7
Vegetables	14.0 ± 4.2	77 (21%)	13.5 ± 4.1	15.9 ± 3.9*
Speeded attention task				
Raw word	105.9 ± 127.6	–	106.3 ± 130.3	104.0 ± 113.7
Raw color	63.3 ± 14.9	–	62.8 ± 18.7	65.8 ± 17.7
Raw word + color	35.9 ± 13.0	–	35.4 ± 14.3	38.1 ± 15.1
Noise pareidolia task				
Yes face	6.93 ± 0.77	–	6.9 ± 0.9	6.9 ± 0.3
No noise	12.59 ± 3.82	–	12.4 ± 1.9	13.5 ± 8.0
Yes face + No noise	19.51 ± 3.81	–	19.3 ± 2.1	20.4 ± 8.1
Motor				
MDS-UPDRS part 3, <i>score</i>	2.07 ± 3.46	72 (24%)	2.15 ± 3.5	1.73 ± 3.29
Purdue pegboard, <i>dominant hand</i>	10.88 ± 2.42	87 (29%)	10.67 ± 2.34	11.77 ± 2.56*
Alternate tap test, <i>dominant hand</i>	174 ± 40	145 (48%)	175 ± 41	172 ± 34
Timed up and go, <i>seconds</i>	9.01 ± 3.23	24 (8%)	8.89 ± 3.24	9.53 ± 4.06
Autonomic				
Supine BP, <i>mm Hg</i>	138 ± 19/80 ± 10	–	139 ± 20/81 ± 11	133 ± 22*/78 ± 11
Supine heart rate, <i>bpm</i>	64 ± 11	–	64 ± 12	66 ± 10
3 min standing BP, <i>mm Hg</i>	128 ± 18/80 ± 11	–	130 ± 28/81 ± 18	122 ± 37*/78 ± 23
3 min standing heart rate, <i>bpm</i>	73 ± 13	–	73 ± 18	76 ± 23*
Orthostatic hypotension (20–30/10–15)	51 (14%)	–	43 (15%)	9 (14%)
Orthostatic hypotension (30/15)	48 (13%)	–	34 (12%)	14 (21%)
Sensory				
Farnsworth-Munsell color vision test	143.7 ± 97.6	226 (74%)	149.3 ± 101.0	119.2 ± 89.0*
Color blindness	22 (6%)	–	20 (7%)	2 (3%)
Brief smell identification test	7.2 ± 3.0	176 (57%)	7.0 ± 3.1	8.2 ± 2.7*
Olfactory symptoms	79 (22%)	–	63 (21%)	87 (24%)

Data are presented as mean ± standard deviation, or raw frequency count with percent of the total number of available responses in parentheses. Criteria for abnormality: Montreal Cognitive Assessment, Z-score at or below 1.5 SD based on total score ≤ 25; MDS-UPDRS part 3, based on total score > 4; Purdue Pegboard, based on total score < 9; Alternate Tap Test, based on total score < 165; Timed Up and Go, based on total time ≥ 13.5 s; Farnsworth-Munsell Color Vision Test, based on total score > 100; Brief Smell Identification Test, based on total score ≤ 8.

BP, blood pressure; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale.

**p* < 0.05 versus male.

between men and women except for younger age of onset and higher antidepressant usage in women. Previous work has described an earlier age of RBD onset in women that can be attributed to previous or current antidepressant

usage.^{51,53} Indeed, in the present study the average age of men and women did not differ, and potential associations between metrics related to RBD severity and sex were associated with a higher rate of antidepressant usage

among women. Of note, there was no sex difference in the duration of time between self-reported RBD symptom onset and enrollment in NAPS, which could have resulted in an earlier age of onset in women if they were being referred more expeditiously than men. Other sex-related differences were largely expected based upon known patterns of sex-specific health conditions, for example, a higher frequency of OSA, hypertension, hypercholesterolemia, and history of TBI in men, compared to a higher rate of arthritis and thyroid disease in women. The higher rate of sexual dysfunction in men compared to women is relevant given sexual dysfunction is one of the earliest signs of autonomic impairment and neurodegeneration. However, sexual dysfunction is commonly poorly tracked in women and may not have been accurately assessed in these participants using the SCOPA-AUT.

Antidepressants are known to cause changes in sleep architecture and polysomnography findings, predominantly during REM sleep (e.g., induce prominent eye movements, suppress REM sleep, and increase REM sleep without atonia, RSWA).^{54–57} Although no studies have prospectively examined polysomnography findings before and after initiating antidepressant treatment, several studies have reported participants with RBD onset occurring shortly after initiating antidepressant treatment.^{58–60} It remains unknown if antidepressant use is unmasking the same neuropathologic process present in typical RBD, or if the pathophysiology differs. Longitudinal follow-up studies, such as those proposed in the second stage of NAPS (i.e., NAPS2) will be necessary to address this controversial and important clinical question. We differentiated participants in the current study based on any previous history of antidepressant usage, given that it is currently unknown how long RBD/RSWA can persist after discontinuation of the presumed offending medication and whether or not long-term usage is associated with a permanent/persistent upregulation of serotonergic and/or noradrenergic systems. In addition to RBD, insomnia, restless legs syndrome and periodic limb movements were also associated with a history of antidepressant usage.

“Soft” neurological abnormalities were very common in our cohort (i.e., RBD+ participants; $n = 305$ or 84%). We confirm that individuals with such findings are appropriate for inclusion in clinical trials since such features are common among RBD patients. We compared RBD+ participants with isolated RBD, who had no neurological abnormalities identified during a very detailed and comprehensive evaluation. Except for higher rate of restless legs syndrome and periodic limb movement disorders in RBD+, there were no other differences between the groups except older age in RBD+ and higher rate of antidepressant usage in the isolated RBD group. These data suggest that isolated RBD participants

may be at an earlier stage of prodromal synucleinopathy rather than having a separate underlying etiology, although this will require longitudinal follow-up for confirmation. Prospective comprehensive evaluations in both groups will provide insights on if, when, and to what phenotype participants with RBD +/- other neurodegenerative signs/symptoms will evolve. The NAPS Consortium is developing a clinical rating scale that encompasses the broad range of neurological dysfunction that is detectable during the prodromal phase of synucleinopathies. We anticipate that this Prodromal Synucleinopathy Rating Scale (PSRS) will serve as a clinical measure of synucleinopathy burden that can be used in neuroprotective clinical trials in RBD. Additionally, all willing current NAPS participants, and future enrollees, will undergo an expanded clinical and biomarker assessment as part of the NAPS Stage 2 (NAPS2) protocol (U19 AG071754) to develop additional biomarkers and achieve readiness for neuroprotective clinical trials.

The possible genetic underpinnings of RBD remain ill-defined. Previous work reported a family history for dream enactment via the RBD1Q⁶¹ to be 13.8% in idiopathic RBD. In the NAPS Consortium cohort, a male preponderance was present in reported RBD family history, 4.7% of fathers versus 0.8% of mothers (Fig. 2). This is consistent with the sex distribution among the probands. Similarly, reported PD was more common among male relatives, while AD and dementia diagnoses were more common in women. While these differences may reflect “expected” sex effects on phenotypic manifestations of synucleinopathies, it remains possible that other unknown mechanisms are potentially contributing. Additional work is needed in better describing the genealogy of RBD, as several limitations to the present data exist. Namely, that participant “unknown” responses, as well as a detailed history of extended family (e.g., presence/absence of siblings, offspring, and aunts/uncles), were not recorded. As such, frequency counts may not accurately reflect true percentages. Data pertaining to participants mother/father and m./p. grandparents likely carry the greatest confidence with respect to frequency counts. All data collected reflected in Fig. 2 are intended to serve as an initial description of this important topic.

Limitations in this study include the cross-sectional and descriptive nature inherent to these data and experimental design. Participants were recruited primarily from clinics offered on a consecutive basis and supplemented with community referrals through the www.naps-rbd.org website. This introduced possible selection bias and may have contributed to the relatively demographically homogenous sample. Information pertaining to individuals who were not enrolled were not retained, and therefore, our understanding of how this primarily




Figure 1. Distribution of scores in primary domains of function. The distribution of individual scores (open circles) with the mean value indicated via the shaded bar and the threshold for abnormality (dotted line) with the percentage of the total cohort falling above/below this threshold and meeting criteria for abnormal function for (A) the Montreal Cognitive Assessment (% abnormal based on Z-score of 1.5 SD or below after normalization), (B) the MDS-UPDRS part III (% abnormal based on total score > 4), (C) the Brief Smell Identification Test (% abnormal based on total score ≤ 8), (D) the SCOPA-AUT (% abnormal based on total score > 13), (E) Farnsworth-Munsell 100 color vision test (% abnormal based on total score > 100), (F) the Alternate Tap Test for participants dominant hand (% abnormal based on total score < 165).




Figure 2. Genealogy of known RBD and related neurologic and sleep disorders. Participant (shaded center box) with offspring, sibling, and maternal (m.) and paternal (p.) family members. Non-shaded circles indicate female sex and non-shaded squares indicate male sex (shaded squares for participant, cousins and non-immediate family imply male or female). Rates for RBD, Dementia (including: Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), and Dementia NOS [no other symptoms]), Parkinson’s Disease (PD), Multiple Systems Atrophy (MSA), other neurological diseases (dz), and other sleep disorders (ds) are listed within each family member. Within the Dementia category, the rate of DLB is indented and indicated. Rates above 1% are bolded for clearer visualization. Note: Raw frequency counts are not embedded due to (1) space constraints, and (2) limitations inherent to these data. All percentages reflect a total sample size of $n = 361$. However, this is only strictly applicable to participants mother/father, and m./p. grandparents, with the greater confidence in these categories denoted by thicker borders. Not all participants have siblings, offspring, m./p. aunts/uncles, cousins, or other non-immediate family members. Further, participant “unknown” responses were not recorded.

clinic-based cohort might compare to a community-based sample remains limited. As previously mentioned, NAPS2 intends to follow these participants longitudinally, with the addition of biofluid, neuroimaging, and other biomarkers. Additionally, data were collected across 10 different sites, and therefore, despite rigorous standardization, inter-site variability may exist. Although this concern is tempered from our rigorous adjudication process, it remains possible that non-detectable inter-site

variability between outcomes exists, and as such, could theoretically be a factor for any outcome. Antidepressant use history was obtained from participants’ report and therefore subject to recall bias. However, our findings are consistent with existing literature on the effects of antidepressants on RBD/RSWA. Family history information is limited by relying completely upon participant recall; additional genetic investigations in the NAPS Consortium and other RBD cohorts will be invaluable in exploring

genetic risks factors for synucleinopathies. Lastly, the present manuscript is intended to be a descriptive report of the NAPS Consortium baseline cohort, and as such, the inclusion of *p*-values throughout the presentation of results should be interpreted knowing that they are not corrected for multiple comparisons, and that issues surrounding selection and confounding were not robustly modeled.

In summary, this multisite dataset represents a coordinated effort to enroll, characterize, and follow a cohort of hundreds of subjects with RBD across North America. Initial results from this current baseline characteristics study already reveal novel insights about sex differences, antidepressant use, heritability, and the breadth and severity of neurological impairment among individuals with idiopathic RBD. Future work is poised to answer critical questions about longitudinal progression of disease, pathophysiological features, biomarkers, and predictors of phenoconversion. Importantly, longitudinal data on this well-characterized cohort will inform the design of future neuroprotective clinical treatment trials, especially those targeting the earliest phase of synucleinopathy.

Acknowledgements

The authors would like to express their sincere appreciation and gratitude for the participation of our research subjects, and to the entire NAPS consortium. Financial support from NIH grants R34 AG056639, U19 AG071754, P50 AG016574, P30 AG62677; VA RRD 1K2 RX002947; and Canadian support via Research Chair in Cognitive Decline in Pathological Aging.

Author Contributions

Conception and design of the study. JEE, MML, ATK, RBP, AP, JFG, EKSL, LKF, JAF, DLB, DEH, AYA, MJH, CHS, JM, SRC, AV, EHD, MGM, DRS, JKLI, BFB, YSJ. Acquisition and analysis of data. JEE, MML, ATK, RBP, AP, JFG, EKSL, LKF, JAF, DLB, DEH, AYA, MJH, CHS, JM, SRC, AV, EHD, MGM, DRS, JKLI, BFB, YSJ. Drafting a significant portion of the manuscript or figures (i.e., a substantial contribution beyond copy editing and approval of the final draft, which is expected of all authors). JEE, MML, ATK, RMP, BFB, YSJ.

Conflict of Interest

• Dr. Elliott has received support from the Department of Veteran Affairs, NIH (NHLBI, NIA, NCCIH), Oregon Medical Research Foundation, Portland VA Research Foundation, Eugene & Clarissa Evonuk

Foundation in Environmental Physiology, and American Heart Association.

- Dr. Lim has received support from Department of Veteran Affairs, Department of Defense, NIH (NIMH, NHLBI, NIA, NCCIH, NINDS, NIGMS, NCATS), NSF, Center for Neuroscience & Regenerative Medicine (Henry Jackson Foundation), Oregon Medical Research Foundation, Collins Medical Trust, Brain & Behavior Foundation (NARSAD), American Sleep Medicine Foundation, Hartford Center of Gerontological Excellence, Pacific Northwest National Laboratory, and Portland VA Research Foundation.
- Allison Keil, Dr. Pelletier, Dr. Forsberg, Jennifer McLeland has no disclosures.
- Dr. Postuma has received support from the Fonds de Recherche du Québec – Santé, the Canadian Institutes of Health Research, the Parkinson Society of Canada, the Weston-Garfield Foundation, the Michael J. Fox Foundation, the Webster Foundation; and personal fees from Takeda, Roche/Prothena, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, Jazz Pharmaceuticals, Abbvie, Janssen, Otsuka, Phytopharmics, Inception Sciences, and Curasen.
- Dr. Gagnon has received support from the NIH, the Canadian Institutes of Health Research and the *Fonds de Recherche du Québec – Santé*.
- Dr. St. Louis has received support from NIH (NIA, NINDS, and NHLBI), the Michael J. Fox Foundation, Harmony, Inc., and Sunovion, Inc.
- Dr. Fields has received support from the NIH.
- Dr. Bliwise has received support from the NIH and has been a Consultant to CliniLabs, Eisai, Ferring, Huxley, Idorsia, and Merck.
- Dr. Huddleston has received support from NIH (NIA, NINDS, Department of Veteran Affairs, the American Parkinson's Disease Association Center for Advanced Research, the Emory Udall Parkinson's Disease Research Center, the Emory Lewy Body Dementia Association Research Center of Excellence, the Emory Alzheimer's Disease Research Center, the Michael J Fox Foundation, the Georgia Research Alliance, the Bumpus Family Foundation, and the McMahon Family).
- Dr. Avidan has received consultant fees from Avadel, Merck, Takeda, Eisai, Idorsia, and Harmony, and speaker honoraria from Merck, Eisai, Harmony, and Idorsia.
- Dr. Howell has received research support from the NIH.
- Dr. Schenck has received a one-time speaker honorarium from Eisai, Inc.
- Dr. Criswell has received support from the NIH and consulting fees from Abbvie and Sio Gene Therapies.

- Dr. Videnovic has received research support from the NIH and the Michael J Fox Foundation; consultancy fees from Alexion Pharmaceuticals, Biogen, XW Pharma, Jazz.
- Dr. Doring has received support from Jazz Pharmaceuticals, Sanofi, Takeda, Rythm Inc., and the Feldman Foundation CA.
- Dr. Miglis has received support from Jazz Pharmaceuticals, Embr Wave, and Biohaven Pharmaceuticals; Consulting fees from 2nd MD, Infinite MD, and Guidepoint LLC; Payments for CME lectures from MED-IQ; Royalties from Elsevier Inc.
- Dr. Shprecher has received support from the Arizona Alzheimer's Consortium, Abbvie, Acadia, Aptinyx, Axovant, Biogen, Eisai, Eli Lilly, Enterin, Neurocrine, Michael J Fox Foundation, NIH, Nuvelution, Theravance, and Teva; consultant fees from Amneal, Forensis, and Neurocrine; speaker honoraria from Acorda, Amneal, Neurocrine, Sunovion, Teva, and US World Meds/Supernus.
- Dr. Lee-Iannotti has received support from NIH, Liva Nova, Respicardia, and the Arizona Alzheimer's Consortium. She serves on the Scientific Advisory Board for Jazz Pharmaceuticals, INSPIRE, and Avadel. She is a consultant and speaker for Jazz Pharmaceuticals.
- Dr. Boeve has served as an investigator for clinical trials sponsored by Alector and Biogen. He serves on the Scientific Advisory Board of the Tau Consortium. He receives support from NIH, the Mayo Clinic Dorothy, and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation.
- Dr. Ju has received support from the NIH and the Centene Corporation contract (P19-00559) for the Washington University-Centene ARCH Personalized Medicine Initiative; and compensation for consultant activities for Applied Cognition.

References

1. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. *Mov Disord.* 2013;28(3):311-318.
2. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? *Neurology.* 2010;74(14):1143-1148.
3. Videnovic A, Y EJ, Arnulf I, et al. Clinical trials in REM sleep behavioural disorder: challenges and opportunities. *J Neurol Neurosurg Psychiatry.* 2020;91(7):740-749.
4. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. *Sleep.* 1986;9:293-308.
5. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. *Nat Rev Dis Prim.* 2018;4(1):19.
6. Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. *Sleep Med.* 2013;14(8):754-762.
7. Marion MH, Qurashi M, Marshall G, Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? *J Neurol.* 2008;255(2):192-196.
8. Gagnon J-F, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. *Lancet Neurol.* 2006;5(5):424-432.
9. Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. *Sleep Med Rev.* 2019;43:37-46.
10. Iranzo A, Stockner H, Serradell M, et al. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. *Mov Disord.* 2014;29(14):1774-1780.
11. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. *Sleep Med.* 2013;14(8):744-748.
12. Postuma RB, Iranzo A, Hogg B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. *Ann Neurol.* 2015;77(5):830-839.
13. Postuma RB, Gagnon J-F, Montplaisir J. Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: the past 10 years. *Sleep Med.* 2013;14(8):763-767.
14. Miglis MG, Adler CH, Antelmi E, et al. Biomarkers of conversion to α -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. *Lancet Neurol.* 2021;20(8):671-684.
15. Doppler K, Jentschke HM, Schulmeyer L, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. *Acta Neuropathol.* 2017;133(4):535-545.
16. Doppler K, Antelmi E, Kuzkina A, et al. Consistent skin α -synuclein positivity in REM sleep behavior disorder – a two center two-to-four-year follow-up study. *Parkinsonism Relat Disord.* 2021;86(April):108-113.
17. Sprenger FS, Stefanova N, Gelpi E, et al. Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. *Neurology.* 2015;85(20):1761-1768.
18. Vilas D, Iranzo A, Tolosa E, et al. Assessment of α -synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. *Lancet Neurol.* 2016;15(7):708-718.

19. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the international rapid eye movement sleep behavior disorder study group. *Sleep Med.* 2013;14(8):795-806.
20. Rosenberg RS, Van Hout S. The American Academy of sleep medicine inter-scoring reliability program: respiratory events. *J Clin Sleep Med.* 2014;10(4):447-454.
21. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord.* 2015;30(12):1591-1601.
22. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement.* 2011;7(3):263-269.
23. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology.* 2008;71(9):670-676.
24. Berry RB, Brooks R, Gamaldo CE, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Version 2.0. Darien, IL; 2012.
25. Sixel-Döring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. *J Clin Sleep Med.* 2011;7(1):75-80.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep.* 1991;14(6):540-545.
27. Marinus J, Visser M, Martínez-Martín P, et al. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. *J Clin Epidemiol.* 2003;56(1):61-67.
28. Blevins CA, Weather FW, Davis MT, et al. The posttraumatic stress disorder checklist for DSM-5: development and initial psychometric evaluation. *J Trauma Stress.* 2015;28:489-498.
29. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. *J Neuropsychiatry Clin Neurosci.* 2000;12(2):233-239.
30. Visser M, Marinus J, Stiggebout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. *Mov Disord.* 2004;19(11):1306-1312.
31. Besser L, Kukull W, Knopman DS, et al. Version 3 of the national Alzheimer's coordinating center's uniform data set. *Alzheimer Dis Assoc Disord.* 2018;32(4):351-358.
32. Gagnon J-F, Postuma RB, Joncas S, Desjardins C, Latreille V. The Montreal cognitive assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. *Mov Disord.* 2010;25(7):936-940.
33. Ferman TJ. National Alzheimer's Coordinating Center Uniform Data Set LBD Module. Neuropsychological Battery Worksheets—Speeded Attention Task. In: Uniform Data Set v3.0. 2015;1-6.
34. Nishio Y, Yokoi K, Mamiya Y, et al. National Alzheimer's Coordinating Center Uniform Data Set LBD Module. Neuropsychological Battery Worksheets—Noise Pareidolia Task. In: Uniform Data Set v3.0. 2015.
35. Mamiya Y, Nishio Y, Watanabe H, et al. The pareidolia test: a simple neuropsychological test measuring visual hallucination-like illusions. *PLoS One.* 2016;11(5):1-13.
36. Podsiadlo D, Richardson S. The timed "up & go": a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc.* 1991;39(2):142-148.
37. Tiffin J, Asher EJ. The Purdue pegboard; norms and studies of reliability and validity. *J Appl Psychol.* 1948;32(3):234-247.
38. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. *Mov Disord.* 2007;22(1):41-47.
39. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clin Auton Res.* 2011;21(2):69-72.
40. Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American autonomic society (AAS) and the European Federation of Autonomic Societies (EFAS). *Clin Auton Res.* 2018;28(4):355-362.
41. Doty RL, McKeown DA, Lee WW, Shaman P. A study of the test-retest reliability of ten olfactory tests. *Chem Senses.* 1995;20(6):645-656.
42. Doty RL. The Brief Smell Identification Test Administration Manual. Sensonics, Inc; 2001.
43. Farnsworth D. Farnsworth-Munsell 100-hue and dichotomous tests for color vision. *J Opt Soc Am.* 1943;33(10):568.
44. Kinnear PR, Sahraie A. New Farnsworth-Munsell 100 hue test norms of normal observers for each year of age 5-22 and for age decades 30-70. *Br J Ophthalmol.* 2002;86(12):1408-1411.
45. Schenck CH, Boyd JL, Mahowald MW. A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. *Sleep.* 1997;20(11):972-981.
46. Elliott JE, Opel RA, Pleshakov D, et al. Posttraumatic stress disorder increases the odds of REM sleep behavior disorder and other parasomnias in veterans with and without comorbid traumatic brain injury. *Sleep.* 2020;43(3):zsz237.

47. Yeung PY, Wong LLL, Chan CC, et al. Montreal cognitive assessment — single cutoff achieves screening purpose. *Neuropsychiatr Dis Treat.* 2020;16:2681-2687.
48. Petersen R. Mild cognitive impairment as a diagnostic entity. *J Intern med.* 2004;256:183-194.
49. Zhou XS, Shahabuddin S, Zahn BR, Babcock MA, Badr MS. Effect of gender on the development of hypocapnic apnea/hypopnea during NREM sleep. *J Appl Physiol.* 2000;89(1):192-199.
50. Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration—an update. *Nat Rev Neurol.* 2018;14(1):40-56.
51. Y EJ, Larson-Prior L, Duntley S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. *Sleep Med.* 2011;12(3):278-283.
52. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain.* 2019;142(3):744-759.
53. Zhou J, Zhang J, Li Y, et al. Gender differences in REM sleep behavior disorder: a clinical and polysomnographic study in China. *Sleep Med.* 2015;16(3):414-418.
54. Schenck CH, Mahowald MW, Kim SW, O'Connor KA, Hurwitz TD. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. *Sleep.* 1992;15(3):226-235.
55. Jozwiak N, Postuma RB, Montplaisir JY, et al. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. *Sleep.* 2006;40(8):462-466.
56. Postuma RB, Gagnon J-F, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? *Sleep.* 2013;36(11):1579-1585.
57. McCarter SJ, St Louis EK, Sandness DJ, et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder. *Sleep.* 2015;38(6):907-917.
58. Bental E, Lavie P, Sharf B. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. *Isr J Med Sci.* 1979;15(7):607-609.
59. Takahashi T, Mitsuya H, Murata T, Murayama J, Wada Y. Opposite effects of SSRIs and tandospirone in the treatment of REM sleep behavior disorder. *Sleep Med.* 2008;9(3):317-319.
60. Schutte S, Doghramji K. REM behavior disorder seen with venlafaxine (Effexor). *Sleep Res.* 1996;25:364.
61. Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for REM sleep behavior disorder: a multicenter validation study. *Mov Disord.* 2012;27(7):913-916.

APPENDIX: A

NAPS Consortium Personnel:

Co-principal Investigators: Yo-El S. Ju and Bradley F. Boeve.

Site Investigators (alphabetical): Alon Y. Avidan, Donald L. Bliwise, Parichita Choudhury, Susan R. Criswell, Emmanuel H. Doring, Jonathan E. Elliott, Julie A. Fields, Leah K. Forsberg, Jean-François Gagnon, Michael J. Howell, Daniel E. Huddlestone, Joyce K. Lee-Iannotti, Miranda M. Lim, Mitchell G. Miglis, Ronald B. Postuma, David R. Shprecher, Erik K. St. Louis, Aleksandar Videnovic.

Study Coordinators and Research Associates: Jennifer McLeland (lead), Sommer Amudson-Huffmaster, Nellie Brushaber, Jae Woo Chung, Joshua De Kam, Adrian Ekelmans, Marissa Keane, Allison T. Keil, Ruth Kraft, Brittany R. Ligman, Colum MacKinnon, Daeva Miner-Rose, Samantha Murphy, Amelie Pelletier, Katherine L. M. Powers, Matthew Stauder, Adreanne Rivera, Sarahmay Sanchez, Rebekah Summers, Luke Tiegan, Paul Timm, Kelsey A. Tucker.

Data management: Peter Tran.

Consultants: Douglas Galasko, Emmanuel Mignot, Carlos Schenck.

The interpretations and conclusions expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the National Institute of Health, or the United States government.